Annual financial reports from Regeneron and Mammoth Biosciences

Regeneron Invests $100M in CRISPR Therapies with Mammoth Biosciences

Apr 25, 2024, 01:45 PM

Regeneron Pharmaceuticals has expanded its presence in the field of gene editing by entering into a significant partnership with Mammoth Biosciences, a Brisbane, CA-based biotech company co-founded by CRISPR pioneer Jennifer Doudna. The collaboration focuses on developing in vivo CRISPR-based gene editing therapies aimed at multiple tissues and cell types. Regeneron will make an upfront payment and equity investment totaling $100 million, along with additional milestone payments. This deal is part of Regeneron's broader strategy to enhance its genetic medicine portfolio, which includes other initiatives like a longstanding research agreement with Intellia Therapeutics targeting the rare disease transthyretin amyloidosis and the acquisition of a gene therapy biotech.